| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1043110197 |
| P356 | DOI | 10.1007/S002130050156 |
| P698 | PubMed publication ID | 9122358 |
| P2093 | author name string | O'Brien CP | |
| Frazer A | |||
| Volpicelli JR | |||
| King AC | |||
| P433 | issue | 1 | |
| P921 | main subject | naltrexone | Q409587 |
| P304 | page(s) | 15-22 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | Psychopharmacology | Q1422802 |
| P1476 | title | Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence | |
| P478 | volume | 129 |
| Q33720707 | "Killing Two Birds with One Stone": Alcohol Use Reduction Interventions with Potential Efficacy in Enhancing Self-Control |
| Q34482577 | A Prospective 5-Year Re-examination of Alcohol Response in Heavy Drinkers Progressing in Alcohol Use Disorder |
| Q44374802 | A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene |
| Q44341917 | A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients |
| Q44340139 | A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients |
| Q37267741 | A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention |
| Q43503059 | Acute and protracted cocaine abstinence in an outpatient population: a prospective study of mood, sleep and withdrawal symptoms |
| Q34516895 | Acute effects of low and high dose alcohol on smoking lapse behavior in a laboratory analogue task |
| Q44609217 | Acute effects of memantine in combination with alcohol in moderate drinkers. |
| Q44977111 | Alcohol effects during acamprosate treatment: a dose-response study in humans |
| Q44346071 | Association of functional opioid receptor genotypes with alcohol dependence in Koreans |
| Q48739532 | Behavioral responses to ethanol in light and moderate social drinkers following naltrexone pretreatment |
| Q44030576 | Biphasic alcohol response differs in heavy versus light drinkers |
| Q44867663 | Building bridges: the transdisciplinary study of craving from the animal laboratory to the lamppost |
| Q34565568 | Choosing the right medication for the treatment of alcoholism |
| Q37391542 | Chronology of alcohol dependence: implications in prevention |
| Q42149212 | Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism. |
| Q36931792 | Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. |
| Q37258181 | Determining the heritability of ethanol-induced locomotor sensitization in mice using short-term behavioral selection |
| Q35215502 | Different phenotypic and genotypic presentations in alcohol dependence: age at onset matters. |
| Q102379344 | Do behavioral pharmacology findings predict clinical trial outcomes? A proof-of-concept in medication development for alcohol use disorder |
| Q50042559 | Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study |
| Q34663975 | Effects of conditioned food aversions on nutritional behavior in humans |
| Q50910134 | Effects of conditioned reward and nonreward cues on the heart rate response to alcohol intoxication in male social drinkers. |
| Q41448487 | Effects of environmental enrichment upon ethanol-induced conditioned place preference and pre-frontal BDNF levels in adolescent and adult mice |
| Q40844399 | Effects of moderate alcohol consumption on the central nervous system |
| Q34348078 | Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers |
| Q41774164 | Effects of naltrexone on alcohol drinking patterns and extinction of alcohol seeking in baboons |
| Q38842262 | Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies. |
| Q51091561 | Effects of naltrexone on alcohol self-administration in heavy drinkers. |
| Q36863387 | Effects of naltrexone on cortisol levels in heavy drinkers |
| Q34941455 | Effects of naltrexone on neural and subjective response to alcohol in treatment-seeking alcohol-dependent patients |
| Q41996370 | Effects of systemic opioid receptor ligands on ethanol- and sucrose seeking and drinking in alcohol-preferring (P) and Long Evans rats |
| Q43070514 | Endogenous opiates: 1997. |
| Q44332439 | Endogenous opioid blockade and impulsive responding in alcoholics and healthy controls |
| Q33818913 | Ethanol consumption: how should we measure it? Achieving consilience between human and animal phenotypes |
| Q35070808 | Examining naltrexone and alcohol effects in a minority population: results from an initial human laboratory study |
| Q38856407 | Experimental psychopathology paradigms for alcohol use disorders: Applications for translational research |
| Q36595143 | Extended-release intramuscular naltrexone |
| Q35950894 | Functional genomics strategies to identify susceptibility genes and treatment targets in alcohol dependence |
| Q37011196 | Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence |
| Q51791744 | Genetic moderators of naltrexone's effects on alcohol cue reactivity. |
| Q37784879 | Genetic variation and brain gene expression in rodent models of alcoholism implications for medication development |
| Q34205530 | Human laboratory paradigms in alcohol research. |
| Q44347200 | Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden |
| Q38036386 | Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone |
| Q36952699 | Initial evidence of an association between OPRM1 and adolescent alcohol misuse |
| Q35172775 | Interaction between family history of alcoholism and Locus of Control in the opioid regulation of impulsive responding under the influence of alcohol |
| Q37832752 | Intramuscular extended-release naltrexone: current evidence |
| Q36492094 | Lactational state modifies alcohol pharmacokinetics in women |
| Q30399592 | Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone |
| Q44453598 | Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers |
| Q43940291 | Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol |
| Q38718932 | Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models |
| Q33965719 | Medications to treat alcoholism. |
| Q36200985 | Methodology of a randomized double-blind clinical trial for comorbid posttraumatic stress disorder and alcohol dependence |
| Q37344738 | Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment |
| Q34288293 | Naloxone blocks ethanol-mediated appetitive conditioning and locomotor activation in adolescent rats |
| Q46577821 | Naloxone does not attenuate the locomotor effects of ethanol in FAST, SLOW, or two heterogeneous stocks of mice |
| Q37351522 | Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial |
| Q51079335 | Naltrexone alteration of acute smoking response in nicotine-dependent subjects. |
| Q37119755 | Naltrexone alters the processing of social and emotional stimuli in healthy adults |
| Q33653182 | Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study. |
| Q52275350 | Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. |
| Q44727564 | Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking |
| Q41664978 | Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic review |
| Q45283214 | Naltrexone for alcohol-dependent patients |
| Q36263819 | Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking |
| Q48439294 | Naltrexone in patients with bipolar disorder and alcohol dependence. |
| Q36589474 | Non-human primate models of inheritance vulnerability to alcohol use disorders |
| Q37262791 | Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype |
| Q44337944 | Opioid antagonists and alcoholism treatment. |
| Q37305010 | Opioid antagonists block the acquisition of ethanol-mediated conditioned tactile preference in infant rats |
| Q24244900 | Opioid antagonists for alcohol dependence |
| Q34438002 | Opioid antagonists in the treatment of alcohol dependence |
| Q34190543 | Opioid modulators for alcohol dependence. |
| Q58692009 | PET imaging reveals lower kappa opioid receptor availability in alcoholics but no effect of age |
| Q37215609 | Penn/VA center for studies of addiction |
| Q36126591 | Pharmacogenetic approaches to the treatment of alcohol addiction |
| Q37201611 | Pharmacogenetic treatments for drug addiction: alcohol and opiates. |
| Q35622645 | Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study |
| Q37932516 | Pharmacogenomics of the human µ-opioid receptor |
| Q36989434 | Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment |
| Q46881184 | Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism |
| Q31034251 | Preliminary data on the association among the serotonin transporter polymorphism, subjective alcohol experiences, and drinking behavior |
| Q46357393 | Preserved DNA from past clinical trials yields new information about a subtype of alcoholism |
| Q31993903 | Pretreatment with hydromorphone, a mu-opioid agonist, does not alter the acute behavioral and physiological effects of ethanol in humans |
| Q44493524 | Prevention of alcohol dependence: strategies for selective, indicated, and universal prevention |
| Q43592750 | Quantitative autoradiography of mu-opioid receptors in the CNS of high-alcohol-drinking (HAD) and low-alcohol-drinking (LAD) rats |
| Q34808075 | Relapse prevention and maintaining abstinence in older adults with alcohol-use disorders |
| Q80658590 | Relationship between the cardiac response to acute intoxication and alcohol-induced subjective effects throughout the blood alcohol concentration curve |
| Q33748928 | Relationship of components of an alcohol interoceptive stimulus to induction of desire for alcohol in social drinkers |
| Q34410153 | Response inhibition impairments predict alcohol-induced sedation |
| Q34474280 | Response to alcohol in women: Role of the menstrual cycle and a family history of alcoholism |
| Q90306884 | Reward, Relief and Habit Drinking: Initial Validation of a Brief Assessment Tool |
| Q44261145 | Role of naltrexone in initial smoking cessation: preliminary findings |
| Q41477480 | Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme |
| Q56681094 | Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study |
| Q38685941 | Subjective Response to Alcohol as a Research Domain Criterion. |
| Q51079565 | Subjective and objective responses to ethanol in moderate/heavy and light social drinkers. |
| Q38464015 | Subjective response as a consideration in the pharmacogenetics of alcoholism treatment. |
| Q36436395 | Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism |
| Q30730816 | Subjective responses to alcohol in the lab predict neural responses to alcohol cues. |
| Q37479990 | Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus |
| Q31993644 | Suppression of ethanol responding by centrally administered CTOP and naltrindole in AA and Wistar rats |
| Q37288935 | Sweet liking phenotype, alcohol craving and response to naltrexone treatment in alcohol dependence |
| Q36589482 | Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone |
| Q34689570 | The Effects of Naltrexone Among Alcohol Non-Abstainers: Results from the COMBINE Study |
| Q48147795 | The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype |
| Q34199824 | The effects of drinking goal on treatment outcome for alcoholism |
| Q30408902 | The efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models |
| Q34336464 | The nicotinic acetylcholine receptor partial agonist varenicline increases the ataxic and sedative-hypnotic effects of acute ethanol administration in C57BL/6J mice |
| Q34543952 | The pharmacotherapy of alcohol dependence: a state of the art review |
| Q33784506 | The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption |
| Q38139197 | The role of the opioid system in alcohol dependence |
| Q46620444 | The subjective, rather than the disinhibiting, effects of alcohol are related to binge drinking |
| Q33940215 | Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues |
| Q37089324 | Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study. |
| Q30440516 | Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings |
| Q34167551 | Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. |
| Q42999527 | What aspects of human alcohol use disorders can be modeled using selectively bred rat lines? |
| Q35820303 | What place does naltrexone have in the treatment of alcoholism? |
Search more.